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Abstract
Background Patients sustaining a fractured neck of the
femur are typically of advanced age with multiple
comorbidities. As a consequence, the proportion of these
patients receiving warfarin therapy is approximately 10%.
There are currently few studies investigating outcomes in
this subset of patients.
Questions/purposes The purpose of this study was to
assess the association between warfarin therapy and time to
surgery, length of hospital stay, and survival in patients
sustaining a fractured neck of the femur.
Methods Data for 2036 patients admitted to our center
between July 2009 and July 2014 with a fractured neck
of the femur were extracted from the National Hip
Fracture Database. Fifty-seven patients received no sur-
gical treatment and were excluded from analysis.
Multivariable ordinary least squares regression was per-
formed to test the association between warfarin treatment
on time to surgery and length of stay, and Cox propor-
tional hazards to test followup survival. Variables
included in the regression model were age, sex, Ameri-
can Society of Anesthesiologists (ASA) score, admission
Abbreviated Mental Test Score (AMTS), fracture type,
operation type, and premorbid Work Ability Index
(WAI). One hundred fifty-two of 1979 surgically treated
patients (8%) were receiving warfarin therapy at the time
of admission.
Results After controlling for age, sex, ASA score, AMTS,
fracture type, operation type, and WAI, we found that
patients taking warfarin were less likely to go to surgery by
36 hours (odds ratio [OR], 0.20; 95% CI, 0.14–0.30), and
less likely to go to surgery by 48 hours (OR, 0.17; 95% CI,
0.11–0.24). Patients taking warfarin had a longer length of
stay (median, 15 days; interquartile range [IQR], 12–22
days) compared with patients not taking warfarin (median,
13 days; IQR, 9–20 days; p\ 0.001). Survival analysis to
June 2015 showed a higher mortality for patients taking
warfarin (12-month survival, 66% vs 76%; hazard ratio,
1.57; 95% CI, 1.21–2.04; p\ 0.001).
Conclusions After controlling for multiple prognostic
factors such as age, ASA score, AMTS, and WAI, warfarin
therapy at the time of injury is associated with increased
time to surgery, length of stay, and decreased survival. This
study highlights the need to view warfarin therapy as a ‘red
flag’ in patients presenting with a fractured neck of the
femur. Preoperatively, prompt warfarin reversal together
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with adequate investigation and optimization of the patient
should ensure timely, safe surgery. Early involvement of
the anesthesia team should ensure an appropriate level of
postoperative care for these patients.
Level of Evidence Level III, therapeutic study
Introduction
Hip fractures account for the majority of orthopaedic
trauma in the United Kingdom (UK), with more than
64,000 cases in England, Wales, and Northern Ireland in
2014 [20]. The condition often affects elderly patients with
multiple comorbidities and consequently has been shown
to have poor clinical outcomes, with mortality at 12 months
as much as 36% [1, 4]. In the United States, at least
250,000 people are hospitalized with hip fractures annually
[6]. This global public health problem is expected to
worsen, with sharp increases in the number of hip fractures
forecast for the next generation [18]. Despite focus on
improving the care of these patients, postinjury mortality
remains stubbornly high [11].
Patients who sustain fragility fractures of the hip often
have concurrent comorbidities, some of which require
anticoagulation with warfarin. Between 7.8% and 10.3% of
all patients admitted with these fractures are receiving
long-term warfarin therapy, which produces a coagulo-
pathic state as expressed by increased International
Normalized Ratio (INR) [8, 9, 25]. This coagulopathy must
be reduced or eliminated before surgery can safely be
performed. The time taken to achieve a safe INR together
with the presence of multiple comorbidities has the
potential to delay surgical treatment, which conflicts with
policy initiatives (such as the 2010 ‘Best Practice Tariff’ in
the UK) that aim to improve patient outcomes by reducing
delays in hip fracture surgery to less than 48 or 36 hours
[5, 19]. Few studies have investigated the degree to which
warfarin therapy is associated with delays to surgery
[2, 7, 8, 16], and the degree to which such warfarin-asso-
ciated care delays are associated with length of stay and
mortality has not been reported, to our knowledge.
We sought to determine whether a patient’s use of
warfarin at the time of admission for a femoral neck
fracture was associated with (1) time to hip-fracture sur-
gery, (2) length of hospital stay, and (3) survival in patients
sustaining a fractured neck of the femur.
Patients and Methods
This retrospective study is reported in accordance with the
STROBE statement for cohort studies. Data for 2036
consecutive patients admitted to a tertiary referral center
with fragility fracture of the femoral neck between July
2009 and July 2014 were extracted from the National Hip
Fracture Database. Fifty-seven patients received no surgi-
cal treatment and were excluded from analysis. One
hundred fifty-two of 1979 surgically treated patients (8%)
Fig. 1 The flow diagram shows
the selection of patient data for
our study.
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were receiving warfarin therapy at the time of admission
(Fig. 1). Internally verified data were collected on the sex,
age, abbreviated mental test score (AMTS), premorbid
work ability index (WAI), American Society of Anesthe-
siologists (ASA) grade, fracture type (intracapsular-
undisplaced, intracapsular-displaced, intertrochanteric,
subtrochanteric, other), operation type (internal fixation,
hemiarthroplasty, or THA), and time to surgery (Table 1).
Warfarin treatment status and admission INR were col-
lected from digital patient records and laboratory reporting
systems manually. Time to surgery was analyzed as a
continuous variable and with specific thresholds to evaluate
the potential association between warfarin treatment and
time to surgery, including the likelihood of having surgery
before the UK’s Best Practice Tariff (\36 hours) [13] and
achieving surgery before a known prognostic time sug-
gested by others as important (\ 48 hours)
[3, 14, 21, 22, 28]. Finally, subgroup analysis was per-
formed on patients with an INR above and below 2.5 to
assess the association between INR value and outcome. A
total of 135 patients were included (Fig. 2). Median INR
was 2.3 (interquartile range [IQR], 2.3–9.0). Of these, 61
patients presented with an INR less than 2.5, with 74
patients presenting with an INR greater than this value.
Equivalent analyses were performed to the whole cohort of
patients included in this study. Discrete groupings were
used instead of INR as a quantitative variable
attributable to the limited sample size (n = 135). Followup
analyses were performed to July 2015.
Statistical Analysis
Initially, a demographic analysis was done to present key
characteristics of the cohort acquired. Variables were
analyzed in a multivariable ordinary least squares regres-
sion for length of stay and the time to surgery, a logistic
regression for the specific time to surgery cutoffs of less
than 36 hours and less than 48 hours, and a Cox propor-
tional hazards model for survival. Odds ratios (OR) and
95% CIs were calculated for logistic regression results and
hazard ratios, and 95% CIs for the Cox proportional haz-
ards model results. Age was modeled using restricted cubic
splines. Categorical and nominal variables were modeled
as factors. Significance threshold for all variables and
interaction terms was set at a probability less than 0.05. All
Table 1. Sample description for patients taking and not taking
warfarin
Measure Taking
warfarin
Not taking
warfarin
Total
Number of patients (%) 152 (8) 1827 (92) 1979 (100)
Age, years (median,
IQR)
84 (80–88) 85 (79–90) 85 (79–90)
Male, number (%) 56 (37) 525 (29) 581 (29)
AMTS, median (IQR) 8 (6–10) 8 (4–10) 8 (5–10)
Fracture type, number (%)
Intracapsular–
undisplaced
15 (10) 164 (9) 179 (9)
Intracapsular–
displaced
82 (54) 883 (48) 965 (49)
Intertrochanteric 45 (30) 662 (36) 707 (36)
Subtrochanteric 10 (7) 114 (6) 124 (6)
Other 0 (0) 4 (0) 4 (0)
ASA grade*, number (%)
5 1 (1) 0 (0) 1 (0)
4 16 (11) 170 (9) 186 (9)
3 91 (60) 932 (51) 1023 (52)
2 38 (25) 651 (36) 689 (35)
1 3 (2) 56 (3) 59 (3)
Operation type, number (%)
Femoral screw 72 (47) 921 (50) 993 (50)
Hemiarthroplasty 79 (52) 840 (46) 919 (46)
THA 1 (1) 66 (4) 67 (3)
Time to surgery
Median hours (IQR) 46 (29–66) 24 (19–40) 25 (19–41)
\ 36 hours, number
(%)
46 (30) 1290 (71) 1336 (68)
\ 48 hours, number
(%)**
82 (54) 1594 (87) 1676 (85)
Length of stay, median
days (IQR)
15 (12–22) 13 (9–20) 13 (9–20)
Survival, number (%)
30-day 138 (91) 1732 (95) 1870 (95)
6-month 115 (76) 1500 (82) 1615 (82)
12-month 101 (66) 1395 (76) 1496 (76)
*American Society of Anesthesiologists (ASA) grade was missing for
21 patients; IQR = interquartile range; AMTS = Abbreviated Mental
Test Score; ** includes patients operated on in\ 36 hours.
Fig. 2 The graph shows the distribution of admission international
normalized ratio where available for the cohort of patients taking
warfarin at the time of admission for hip fracture.
123
Hip Fractures in Patients Taking Warfarin
analyses were conducted using the rms package in R ver-
sion 3.2.1 [12, 15]. Graphic production was completed
using the ggplot2 package in R, version 3.2.1 [27].
The project was approved by and registered with the
center’s quality improvement team. The National Hip
Fracture Database is a national audit in the UK approved
by the National Health Service (NHS) England Health
Research Authority (HRA) Confidentiality Advisory
Group.
Results
Time to Surgery
After controlling for sex, age, AMTS, WAI, ASA grade,
fracture type, and operation type, patients taking warfarin
went to surgery later than those not treated with warfarin
(Table 2) (f = 86.8; p\0.001). Results were consistent when
analyzing time-interval thresholds; patients taking warfarin
were less likely to go to surgery by 36 hours (OR, 0.20; 95%
CI, 0.14–0.30) and less likely to go to surgery by 48 hours
(OR, 0.17; 95% CI, 0.11–0.24). Median time to surgery was
substantially higher in patients treated with warfarin (median,
46 hours; IQR, 29–66) compared with patients not treated
(median, 24 hours; IQR, 19–40). A higher INR did not mean
patients were less likely to go to surgery (Supplemental
Table 1 [f = 0.3; p = 0.576]. Supplemental material is
available with the online version of CORR1).
Length of Stay
After controlling for sex, age, AMTS, WAI, ASA score,
fracture type, and operation, length of stay was found to
be increased in patients treated with warfarin (Table 3)
(f = 13.05; p \ 0.001). Patients treated with warfarin
recorded a median length of stay of 15 days (IQR, 12–22
days) compared with 13 days (IQR, 9–20 days) for those
not treated with warfarin. A higher INR was not asso-
ciated with greater length of stay (Supplemental Table 2
[f = 0.07; p = 0.787]. Supplemental material is available
with the online version of CORR1).
Survival
After controlling for age, sex, ASA score, AMTS, WAI,
fracture type, and operation, treatment with warfarin was
found to be associated with reduced survival with time (chi
square = 12.7; p\ 0.001) (Table 4). The hazard ratio for
warfarin treatment was 1.57 (95% CI, 1.21–2.04). Unad-
justed survival was lower throughout followup for patients
taking warfarin (chi square = 9.9; p = 0.002) (Fig. 3). A
higher INR was not associated with reduced followup
survival (Supplemental Table 3 [chi square = 0.1, p =
Table 2. Multivariable regression results showing factors related to time to surgery
Factor Time to surgery (hours) \ 36 hours \ 48 hours
df f p value df Chi square p value df Chi square p value
Sex 1 4.9 0.028 1 0.5 0.484 1 1.5 0.219
Age 4 1.6 0.161 4 7.0 0.138 4 2.0 0.741
AMTS 1 3.7 0.054 1 6.9 0.009 1 4.4 0.037
WAI 8 0.9 0.522 8 11.5 0.177 8 1.3 0.996
ASA grade 4 7.6 \ 0.0001 4 10.1 0.039 4 18.6 0.001
Fracture type 4 2.3 0.059 4 2.4 0.656 4 2.9 0.575
Operation type 2 5.2 0.006 2 11.2 0.004 2 12.0 0.002
Warfarin 1 86.8 \ 0.0001 1 69.9 \ 0.0001 1 89.1 \ 0.001
AMTS = Abbreviated Mental Test Score; WAI = Work Ability Index; ASA = American Society of Anesthesiologists.
Table 3. Multivariable regression results showing factors related to
length of stay
Factor df f p value
Sex 1 23.49 \ 0.001
Age 4 3.53 0.007
AMTS 1 44.32 \ 0.001
ASA grade 3 12.03 \ 0.001
Fracture type 4 2.84 0.023
WAI 8 1.98 0.045
Operation type 2 2.23 0.108
Warfarin 1 13.05 \ 0.001
AMTS = Abbreviated Mental Test Score; ASA = American Society
of Anesthesiologists; WAI = Work Ability Index.
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0.767]. Supplemental material is available with the online
version of CORR1).
Discussion
Fractures of the femoral neck are a rapidly growing inter-
national public health problem. Many of the patients who
sustain this injury are elderly with multiple comorbidities,
some of which require the use of warfarin therapy. The
resultant coagulopathy together with the presence of these
comorbidities has the potential to delay treatment and
subsequently affect outcomes. We found that in our patient
population, after controlling for age, sex, ASA score,
AMTS, WAI, fracture type, and operation, that warfarin
therapy is associated with increased time to surgery, length
of stay, and decreased survival.
This study used data from the National Hip Fracture
Database together with the digitally stored components of
hospital patient records. Although this approach was
practical for the large number of patients involved and
allowed a wide range of relevant information to be gath-
ered, it was not exhaustive in its level of detail. Some
relevant information was contained only in the patient’s
‘‘paper’’ hospital notes, the majority of which are retained
at a storage facility not in our center and with very limited
access for research purposes. In particular, we were unable
to control more precisely for comorbidity in our analysis.
Although our study controlled for ASA grade, which has
been shown to accurately reflect medical comorbidity and
the likelihood of medical complications and mortality after
surgery, this does not allow accurate conclusions to be
drawn regarding the causes of differing outcomes between
the two groups [10, 17]. Similarly, our data did not contain
detailed information regarding the reasons for delays to the
operating room. There are several possible difference
between the two groups in this regard. The most common
indication for warfarin therapy in this group of patients is
atrial fibrillation (83%), followed by thromboembolic dis-
ease (18%), and mechanical heart valve (5%), with
approximately 7% having multiple indications [9]. These
comorbidities may cause delays in time to the operating
room owing to the time needed to appropriately investigate
and optimize the patient before administration of anesthe-
sia. Similarly, the time taken to reverse the warfarin-
induced coagulopathy using reversal agents in these
patients may be a cause of delay. Future studies investi-
gating the cause of these differences would need detailed
analysis of drug cards and patient notes that were not
possible for this study. This will be aided by the use of
digital recordkeeping, which is becoming increasingly
popular across the UK. Although our study involves a
relatively large cohort of 1979 patients, the number taking
warfarin was comparatively small. This did not allow for
detailed subgroup analysis, which would have enabled us
to draw more detailed conclusions regarding the relation-
ship between admission INR and clinical outcome.
Table 4. Cox proportional hazards survival model
Factor df Chi square p value
Sex 1 35.0 \ 0.001
Age 4 31.5 \ 0.001
AMTS 1 58.0 \ 0.001
WAI 8 27.9 0.001
ASA grade 4 101.5 \ 0.001
Fracture type 4 12.2 0.016
Operation type 2 6.1 0.047
Time to surgery 1 0.0 0.912
Warfarin 1 12.7 \ 0.001
AMTS = Abbreviated Mental Test Score; WAI = Work Ability Index; ASA = American Society of Anesthesiologists.
Fig. 3 The survival curves show the effect of warfarin treatment
status on survival.
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We found that after controlling for age, sex, ASA score,
AMTS, WAI, fracture type, and operation type, warfarin
therapy was associated with increased time to surgery. This
delay has been reported in previous studies [7, 8, 16, 24],
although our study is the first, to our knowledge, showing
the same association after regression analysis using these
prognostic factors. Ryan et al. [21] conducted a study with
more than two million patients sustaining a fractured neck
of the femur and reported that a time to the operating room
in excess of 48 hours resulted in higher mortality, with an
OR of 1.13 for the delayed group after controlling for
multiple prognostic factors including comorbidity. They
also showed this risk increased with time, with patients
who had surgery more than 3 days after admission having a
substantially increased risk of death (OR, 1.33). Our study
is the most comprehensive to date to show association
between warfarin therapy and delays to the operating room,
and therefore should highlight the need to prevent any
avoidable preoperative delays in these patients. Early
warfarin reversal together with adequate investigation and
optimization of these more complex patients could ensure
timely, safe surgery [2, 7–9, 23, 26].
Patients receiving warfarin at the time of hospital
admission for femoral neck fracture had longer lengths of
hospital stay. Previous studies have come to differing
conclusions regarding this matter. Ranhoff et al. [16], in a
2011 study of 1192 patients with hip fracture, found longer
length of stay for warfarin users compared with nonusers.
Conversely, Eardley et al. [8], in a [2014 study of 1024
patients, showed no association between length of stay and
the use of warfarin at the time of admission for hip fracture.
Our study differs from both of these in that we have con-
trolled for age, sex, ASA score, AMTS, WAI, fracture type,
and operation type in our analysis. Our study therefore
provides the most robust evidence to date that warfarin
users experience longer hospital stays after hip fracture.
We found that patients taking warfarin before their hip
fractures were more likely to die during the 12 months after
hip-fracture surgery. This is the first study, to our knowl-
edge, to show poorer survival in this group of patients. This
should encourage clinicians to treat warfarin therapy as a
‘red flag’ in patients sustaining a fractured neck of the
femur and ensure all necessary steps are taken to ensure
early surgery, involvement of all the appropriate medical
teams, and appropriate levels of postoperative care.
Our study showed an association between warfarin
therapy at the time of admission for hip fracture and out-
come as measured by time to surgery, length of stay, and
survival. Clinicians should ensure this complex group of
patients receive an appropriate level of postoperative care,
with early involvement of the anesthesia team. Warfarin
should be recommenced in a timely manner to ensure a
therapeutic INR is achieved when the patient is clinically
fit for discharge. Further studies should focus on estab-
lishing the cause of these poor outcomes and identify areas
for improvement in the care of these patients.
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